Deborah Phippard, PhD

Deborah Phippard, PhD, shared her thoughts with Renier Brentjens, MD, PhD, on reducing costs for cell and gene therapy products.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, shared their thoughts on the future of cell and gene therapy.

Deborah Phippard, PhD, shared her thoughts with Renier Brentjens, MD, PhD, about the importance of big wins for cell and gene therapy research.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, shared advice for young scientists entering the cell and gene therapy field.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, discussed the unpredictability of "living drugs" in the human body and the ongoing development of understanding.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, shared their thoughts on how streamlined collaboration can help move therapies to patients faster.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, discussed strategies used to streamline development in cell and gene therapy.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, discussed the major friction points in cell and gene therapy development and uptake.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, discussed their thoughts on major moments in the past 25 years of cell and gene therapy research.

The chief scientific officer of Precision for Medicine discussed unique difficulties of designing clinical trials for PD gene therapy candidates.

The chief scientific officer of Precision for Medicine discussed what lies on the horizon for gene therapies directed at neurological indications, such as Alzheimer disease and Parkinson disease.

The chief scientific officer of Precision for Medicine discussed the unique aspects of clinical trials for gene therapies that need to be considered before initiation.

The chief scientific officer of Precision for Medicine discussed the previous and current delivery methods used for gene therapies and new innovations on the horizon.